Prognostic value of late potentials in patients with congestive heart failure

M Galinier1, J P Albenque, N Afchar

  • 1Cardiology Division, Rangueil University, Toulouse, France.

European Heart Journal
|February 1, 1996
PubMed

Insights

Signal-averaged ECG detection of ventricular late potentials in congestive heart failure patients did not predict overall mortality or sudden death. However, late potentials significantly identified patients at higher risk for sustained ventricular tachycardia.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Diagnostics

Background:

  • Congestive heart failure (CHF) is associated with increased risk of ventricular arrhythmias.
  • Ventricular late potentials (VLPs) on signal-averaged ECG (SAECG) are potential markers of arrhythmogenic substrate.
  • Prognostic value of VLPs in CHF, with or without bundle branch block (BBB), requires further investigation.

Purpose of the Study:

  • To determine if VLPs detected by SAECG provide prognostic information in CHF patients.
  • To assess the association of VLPs with mortality, sudden cardiac death, and sustained ventricular tachycardia (SVT).
  • To evaluate the utility of VLPs in risk stratification for CHF patients, including those with BBB.

Main Methods:

  • Prospective study of 151 CHF patients (57 with BBB) undergoing SAECG.
  • VLPs were analyzed, and patients were followed for mortality, sudden death, and VT events.
  • Subgroup analyses were performed excluding patients with BBB, severe CHF, or amiodarone use.

Main Results:

  • VLPs were detected in 32.5% of CHF patients, with similar incidence in patients with and without BBB.
  • VLP presence was not correlated with age, NYHA class, ejection fraction, or amiodarone use.
  • Total mortality, cardiac mortality, and sudden death risk were not significantly related to VLPs.
  • However, patients with VLPs had a significantly higher incidence of prior and follow-up SVT (18% vs 2%, P < 0.001).

Conclusions:

  • SAECG detection of VLPs in CHF patients does not reliably predict overall mortality or sudden death risk.
  • VLPs improve risk stratification specifically for sustained ventricular tachycardia in CHF patients.
  • The prognostic value of VLPs is limited to identifying patients at increased risk for VT events, irrespective of BBB or CHF severity.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
329
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
305
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
894
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
865
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963